(UroToday.com) Approximately half of the patients with advanced urothelial carcinoma in the United States are cisplatin-ineligible. Of note, cisplatin-ineligible, platinum-naive patients with locally advanced or metastatic urothelial carcinoma who progress on or after anti-PD-1/L1 treatment have a poor prognosis and few treatment options. Enfortumab vedotin, a Nectin-4-directed antibody-drug conjugate, demonstrated an overall survival benefit in patients with locally advanced or metastatic urothelial carcinoma who previously received anti-PD-1/L1 treatment and platinum-containing chemotherapy in EV-3011. EV-201 is a pivotal, single-arm, 2-cohort study. Cohort 2 enrolled cisplatin-ineligible patients with prior anti-PD-1/L1 treatment and no prior platinum for locally advanced or metastatic urothelial carcinoma. Previously presented (and now published) primary analysis results of EV-201 Cohort 2 included an overall response rate of 52% and a complete response rate of 20%, with a median duration of response of 10.9 months2. At the 2021 American Society of Clinical Oncology (ASCO) annual meeting, Dr. Bradley McGregor and colleagues presented updated results with three additional months of follow-up in which all responders were followed for ≥ 6 months after the onset of response.